Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12-months of Maintenance Therapy (AFT-29)
- Citation:
- Blood vol 36 (Supplment 1) 45-46
- Meeting Instance:
- ASH 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Funding:
- AFT
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3304
- Pharmas:
- Janssen Oncology
- Grants:
- Corr. Author:
- Authors:
- Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr Nitya Nathwani Nina Shah Yvonne A. Efebera Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Yana Lutska Cynthia Haines Huiling Pei Jon Ukropec Jessica Vermeulen Thomas S. Lin Paul G. Richardson Peter M. Voorhees
- Networks:
- CA043, CA136, CA249, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, OH008, OR013
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: